InventisBio Co., Limited (SHA:688382)
14.38
-1.09 (-7.05%)
Oct 22, 2026, 4:00 PM EDT
InventisBio Revenue
InventisBio had revenue of 10.78M CNY in the quarter ending June 30, 2026, a decrease of -1.80%. This brings the company's total for the last twelve months to 71.44M, down -58.72% year-over-year. In the year 2025, InventisBio had annual revenue of 37.29M, down -77.91%. That makes InventisBio the 37,023rd largest company in the world by revenue and 5,126th in China.
Revenue (ttm)
71.44M
Revenue Growth
-58.72%
P/S Ratio
116.66
Revenue / Employee
374.06K
Employees
191
Market Cap
8.33B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 37.29M | -131.50M | -77.91% |
| Dec 31, 2024 | 168.79M | -16.74M | -9.02% |
| Dec 31, 2023 | 185.53M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Pacific Shuanglin Bio-pharmacy | 2.48B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.03B |
| Vcanbio Cell & Gene Engineering Corp., | 1.40B |
| Liaoning Chengda Biotechnology | 1.36B |
| Chengdu Easton Biopharmaceuticals | 1.34B |
| Mabwell (Shanghai) Bioscience | 873.99M |
| Shanghai OPM Biosciences | 630.86M |